BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Allenex AB Spins off Novahep AB and Recopharma AB


8/25/2011 6:41:13 AM

STOCKHOLM--(BUSINESS WIRE)-- Allenex (STO:ALNX.st - News) transfers its holdings in the portfolio companies NovaHep AB and Recopharma AB to Alden Impact Capital AG, Zurich, who takes responsibility for the continued financing of their activities.

In NovaHep, focusing on liver stem cells, has Allenex been shareholder since 2005 and in Recopharma, with a focus on recombinant glyco proteins, since 2003. Allenex has been the sole financier of the companies' development work. Both companies have achieved valuable and promising results while there is still much work to be done before they can be commercialized.

Allenex focus is now on the transplantation sector and in terms of liquidity the company prioritizes those activities. Agreement has now been reached with Alden Impact Capital AG, Zurich, a Swiss private equity manager linked to a family office, on the transfer of the holdings in NovaHep and Recopharma. The agreement includes a part of the future profits when Alden Impact Capital AG sells the holdings. Allenex will report a small loss in the second quarter of 2011 of SEK 280 thousand. A greater impairment of the holdings took place during the first quarter of 2011.

"Today, it is extremely difficult to find financing of the development work carried out by NovaHep and Recopharma," says Anders Karlsson, CEO of Allenex. "It is therefore very satisfying that we by the transfer to Alden Impact Capital AG can ensure that both companies will be able to continue their operations."

"NovaHep and Recopharma are two companies with a very exciting focus," says Stefan von Euw, Alden Impact Capital AG. "We will be able to financially support the continued development and so reach the next milestones."

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:10 (CET) on August 25, 2011

Allenex’s business focus is mainly on the transplantation business with subsidiary product companies AbSorber and Olerup SSP and the sales and distribution companies Olerup Inc. and Olerup GmbH. Allenex has also a portfolio of associated life science companies. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX).

www.allenex.com

For more information about Alden Impact Capital, please visit www.aldenimpact.com

This information was brought to you by Cision http://www.cisionwire.com

Contact:

Allenex ABAnders Karlsson, CEOtel: +4670-918 0010email: anders.karlsson@allenex.seorOkee Williamstel: +4670-60 053 64email: okee.williams@allenex.seorAlden Impact Capital AGStefan von Euwtel: +41 79 277 7581email: stefan@aldencapital.ch



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->